Live Chat

交易 BioNTech BNTX

BioNTech 实时图表

金融票据基础知识

Weekly Search
Weekly
Daily
日期 关闭 更改 更改(%): 开盘价

新闻

信息

点差

0.7902

点差(%)

0.7099 %

杠杆

1:10

隔夜利息(买入)

-0.0597 %

隔夜利息(卖出)

-0.0292 %

币种

USD

交易时间

市场关闭

星期一

13:31 - 19:59

星期二

13:31-19:59

星期三

13:31-19:59

星期四

13:31-19:59

星期五

13:31-19:59

分析和统计

开盘价

---

昨收

---

52 周高点/低点

--- – ---

市值

25565874176

在外流通股份

239740000

财报日(下一)

0000-00-00

股息收益率

2022-06-17

除息日

2022-06-02

远期年度股息率

0

远期年股息率

0

每股收益

-2.03

详细了解此金融票据

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

相关金融票据

资产
出售
买入
更改(%):
相关金融票据

最新新闻

时刻了解全球各地的最新金融资讯。

星期三, 6 十一月 2024

U.S. presidential election market volatility drives Bitcoin prices to reach a historic high

Stock market rally

星期二, 5 十一月 2024

US Election Results Trigger Stock Gains Across Europe, Asia, and US

US Election Trump's victory

星期二, 5 十一月 2024

Trump Victory Spurs Market Gains and Economic Shift Expectations

星期二, 5 十一月 2024

US election: bitcoin price (BTC) surged to new record as Trump leading ahead

星期二, 5 十一月 2024

Stock Market Today: Wall Street Rallies on Election Day Amid Strong Economic Outlook

US Election 2024 Trump

星期二, 5 十一月 2024

Early Election Results Shift Markets as Trump’s Chances Rise

星期一, 4 十一月 2024

Stock Market Today: S&P 500 Declines as Investors Brace for US Election

星期一, 4 十一月 2024

US election: What will happen to tesla stock if Trump wins?

Trustpilot
Live Chat